Conducting an orchestra and conducting a pivotal study have more in common than you'd think. 🎼 Both require precision, rhythm, and total alignment across every section, from R&D to regulatory, from partners to patients. Learn more about our Virtue Trial, now enrolling patients: https://lnkd.in/gs_RUhrY #OrchestratingInnovation
Orchestra BioMed
Biotechnology Research
A biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine.
About us
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Under these collaborations, Orchestra BioMed advances its promising therapeutic solutions through late-stage clinical research and regulatory approvals, while its collaborators focus on leveraging their commercial expertise and existing infrastructure to bring these product candidates to global markets quickly and efficiently. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT™)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed has additional product candidates and plans to potentially expand its product pipeline through acquisitions, strategic collaborations, licensing and organic development. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com.
- Website
-
https://www.orchestrabiomed.com
External link for Orchestra BioMed
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Type
- Public Company
- Founded
- 2017
Employees at Orchestra BioMed
Updates
-
Collaboration fuels innovation. 🚀 Avi Fischer and Darren R. Sherman share how community engagement powers progress across the treatment paradigm. #OrchestratingInnovation #MedTech #PhysicianCommunity
-
Behind every milestone, there’s a maestro in motion. 🎶 Norbert Rosenthal is an example of the relentless drive and precision our team brings to every project. Shout out to Norbert for keeping the beat going strong in support of our AVIM therapy program. #OrchestratingInnovation
-
-
Find our Q3 2025 financial results and business updates here: https://lnkd.in/gZSTuC-K #OrchestratingInnovation #News
-
-
Our Chairman & CEO David Hochman will join peers driving meaningful partnerships and innovation across #MedTech, #BioTech, and beyond at Jefferies London next week. See you there! #OrchestratingInnovation #JefferiesHealthcareConference
-
-
Join us for a discussion on our recent business developments and how we’re #OrchestratingInnovation through our partnership-enabled model. 📅 November 12 at 8am ET 📍 Webcast Highlights: 🔸 Additional strategic investment from and collaboration expansion with Medtronic 🔸 New strategic capital relationship with Ligand 🔸 New right of first refusal agreement with Terumo 🔸 Initiation of patient enrollment in the Virtue SAB US pivotal IDE coronary trial 🔸 Acceleration of enrollment in the BACKBEAT pivotal study of AVIM Therapy Register here: https://lnkd.in/gDaGctPa #MedTech #InnovationInHealthcare
-
-
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements 🤝 New agreement supersedes prior distribution agreement and grants Terumo Virtue SAB coronary indication right of first refusal 🤝 Terumo to pay a total of $30 million to Orchestra BioMed 🤝 Orchestra BioMed retains all development and distribution rights to Virtue SAB in all indications 🤝 Orchestra BioMed recently initiated patient enrollment for the Virtue Trial, its U.S. pivotal IDE trial of Virtue SAB in the treatment of coronary in-stent restenosis (“ISR”) Read more: https://lnkd.in/gevkKdJn #OrchestratingInnovation #Partnerships #MedTech
-
Orchestra BioMed Announces First Patients Enrolled in Virtue SAB US Pivotal IDE Coronary Trial 🔸 Orchestra BioMed’s Virtue SAB is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release sirolimus (“SirolimusEFR”) 🔸 The Virtue Trial is the first U.S. IDE head-to-head randomized coronary pivotal trial evaluating a sirolimus-eluting balloon versus a commercially available paclitaxel-coated balloon (AGENT™) 🔸 Coronary ISR, the clinical focus of the Virtue Trial, is a difficult-to-treat and serious complication of coronary stenting that increases the risk of life-threatening heart problems, affecting an estimated 100,000 patients in the U.S. annually 🔸 Virtue SAB has FDA Breakthrough Device Designation for the treatment of coronary ISR, as well as for coronary small vessel disease and below-the-knee peripheral artery disease Read more: https://lnkd.in/gs_RUhrY #OrchestratingInnovation #Cardiology #MedTech
-
Our team is heading to TCT 2025! 🎶 Join Darren R. Sherman, Amy Orlick Berman, Heather Buckley, Bill Little and Donald Klein in San Francisco as they connect with fellow innovators shaping the future of #InterventionalCardiology. #OrchestratingInnovation #TCT2025
-
-
Avi Fischer, M.D., joined forward-thinking leaders exploring the future of treating hypertensive heart disease and helped spotlight the next wave of medtech innovation as a Shark Tank judge at the Georgia Medtech Innovation & Investment Summit. #OrchestratingInnovation #GAMedtechSummit
-